Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04553445 · ClinicalTrials.gov registry record · NA
Temporal, Environmental, and Genetic Factors Regulating Exercise and Migraine
A NA study, sponsored by University of Nevada, Las Vegas.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT04553445: Completed NA study, sponsored by University of Nevada, Las Vegas.
NCT04553445 is a NA study that has completed, run by University of Nevada, Las Vegas. The registered enrollment target is 18 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04553445, a NA study, has completed, sponsored by University of Nevada, Las Vegas.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
Chronic pain, of which migraine is among the most common, affects 100 million US adults and costs between $560 to $635 billion dollars annually. There is a need for effective, low-cost non-pharmacological strategies to reduce migraine load in migraineurs (based on International Headache Society classification International Classification of Headache Disorders \[ICHD\]-3; experience headache \[migraine-like or tension-type-like\] on 15+ days/month for 3+ months, and have migraine headaches \[either with aura or without aura\] on 8+ days/month). This represents an area of interest, as common migraine medications induce central nervous system side-effects including aphasia, ataxia, somnolescence, and vertigo; and 79% of suffers have an interest in trying novel treatment strategies with lower adverse effects than medications. Exercise has been shown to be a non-pharmacological intervention to reduce migraine burden. However, how environmental (i.e. - time-of-day, exposure to nature) and genetic factors (i.e. - polymorphisms in circadian and migraine associated genes) impact the laudatory effects of exercise remains unknown. There are independently established heritable components to migraine frequency (65%), circadian rhythm (70%), and aerobic power during exercise (66%). Thus, the central hypothesis is that an optimal environment can improve the exercise-induced reduction in migraine load, which is influenced by genetic heritability of migraine related gene polymorphisms.
Primary Outcome
The Migraine Disability Assessment (MIDAS) is a 5 question assessment which asks participants to recall the number of days activities were affected due to migraine: 1) days of work or school missed, 2) days where productivity at work or school was affected, 3) days not completing housework, 4) days where housework productivity was affected by more than half, 5) days missed family, social, or leisure activities. The assessment will be completed before and after one month of exercise completed in
Interventions
- BEHAVIORAL Chronotype
- BEHAVIORAL Green exercise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-11-23 |
| Est. Completion | 2022-05-31 |
| Phase | NA |
What the finished NCT04553445 record still lists
NCT04553445 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Chronotype is the first listed.
NCT04553445 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04553445 about?
NCT04553445 is a clinical study titled "Temporal, Environmental, and Genetic Factors Regulating Exercise and Migraine". Chronic pain, of which migraine is among the most common, affects 100 million US adults and costs between $560 to $635 billion dollars annually. There is a need for effective, low-cost non-pharmacological strategies to reduce migraine load in migraineurs (based on International Headache Society clas...
What is the current status of trial NCT04553445?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2020-11-23. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT04553445?
The interventions under investigation include: Chronotype (BEHAVIORAL), Green exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT04553445?
This trial is sponsored by University of Nevada, Las Vegas, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04553445's enrollment target sits among peer trials
18 1863rd of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI